Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16732103 | 0.85 | CA1 (0.37) | CA1CA2CYP4F2CYP4A11CETP | |
| SCHEMBL13980755 | 0.80 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL20572978 | 0.79 | CHRM1 (0.33) | CA2CETPPTGIR | |
| SCHEMBL4687488 | 0.76 | CYP3A4 (0.34) | CA1CA2CYP4F2CYP4A11NPSR1 | |
| SCHEMBL1505478 | 0.76 | CA1 (0.36) | CA1CA2ZDHHC7SMN1; SMN2ALDH1A1 | |
| SCHEMBL16732049 | 0.69 | ALDH1A1 (0.36) | NPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10869871 | 0.69 | CYP4F2 (0.34) | CA1CA2CYP4F2CYP4A11CETP | |
| SCHEMBL7207409 | 0.68 | NPSR1 (0.36) | CYP4F2CYP4A11CETPNPSR1SMN1; SMN2 | |
| SCHEMBL12133355 | 0.66 | — | — | |
| SCHEMBL7745402 | 0.64 | DPP4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473518-B | Bisphosphonic acid compounds | 株式会社富士药品 | 2021-07-06 | — | — | CN | disclosed |
| US-10689408-B2 | Bisphosphonic acid compound | FUJIYAKUHIN CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | FUJIYAKUHIN CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3409679-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | Fuji Yakuhin Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689408-B2 | Bisphosphonic acid compound | SOST, PTH1R, BMP2 | CA1 396/4885CA2 20/4885CYP4F2 2578/4885 |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | SOST, PTH1R, BMP2 | CA1 416/4885CA2 24/4885CYP4F2 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.